Collaboration Results Sample Clauses

Collaboration Results. Once each Calendar Quarter Ginkgo will provide reports on its technical progress relating to the Development and Scale Up of Target Cannabinoids under all existing TDPs to the JSC. Such reports will include supporting documents, such as laboratory records, test results, plans, and other data that may reasonably be requested by the JSC. Any information disclosed by Ginkgo to Cronos pursuant to this Section 2.9 shall be considered Confidential Information of Ginkgo and may be used only in accordance with rights expressly granted under this Agreement. The JSC may also agree to other meetings or other conferences as deemed reasonably necessary by members of the JSC.
Sample 1
AutoNDA by SimpleDocs
Collaboration Results. Subject to the terms and conditions of this Agreement, (a) Molecular Partners will exclusively own all MP Collaboration Results, (b) Allergan will exclusively own all AGN Collaboration Results, and (c) each Party will jointly own all Joint Collaboration Results. Except as otherwise provided in this Agreement, each Party shall have the right to use and exploit the Joint Collaboration Results for any purpose without the duty of accounting or seeking consent from the other Party. Each Party shall notify the other Party promptly after developing any Collaboration Results of which the other Party is the exclusive owner. Each Party shall assign and hereby assigns to the other Party its entire right, title and interest in and to the Collaboration Results and all intellectual property rights therein as needed to implement the ownership of the Collaboration Results in accordance with the provisions of Section 2.12.
Sample 1
Collaboration Results. The Vermont PCO and OMH coordinate closely in efforts to further meet the needs of both of these specific populations. To address the migrant farmworker population’s needs the PCO and OMH have worked with the Bi-State Primary Care Association and several FQHCs to create the Vermont Farm Health Connection, which conducts health outreach and screenings to migrant dairy farmworkers in several counties. Vermont dairies are large, highly mechanized operations. Migrant workers typically reside on the grounds of these farms and work as many as 70 hours in a six-day workweek. This leaves limited time for seeking access to needed health services. The Vermont Farm Health Connection is supported in part by a grant from the federal Office of Rural Health Policy. It provides work safety, nutrition education, and basic health education to farmworkers, many of whom come from rural farming communities in Mexico. Additionally, the PCO and OMH have coordinated with the University of Vermont to establish health outreach to seasonal farmworkers in the state’s fruit and apple orchards. This effort provides primary care, health education, and screening services to migrant farmworkers. Staff with Spanish-language skills provide the services. This effort supplements the work of FQHCs, which do not currently have the capacity to provide these targeted services. To focus on the needs of the diverse immigrant populations the PCO and OMH have worked with Vermont’s Comprehensive Cancer Control program to arrange breast and cervical cancer screening services for immigrant women in the Burlington area. As part of this effort, an FQHC conducts community outreach to immigrant women between ages 40-65 from 12 different cultural and language groups. Promotoras—lay Hispanic or Latino community members who have received training to provide basic health education in their communities—who are familiar with the different groups conduct outreach and education activities. Where necessary, call-in translation services are utilized. Women participating in the program return repeatedly for the FQHC’s services. Summary Although they both have limited resources, the Vermont PCO and OMH, have been able to meet the health needs of migrant workers, refugees, and immigrants in the state by working with external partners. This is a successful model for smaller states with relatively small budgets.
Sample 1
Collaboration Results. During the Research Term, for each Collaboration Target, Molecular Partners shall not publicly disclose any Collaboration Results related directly to AGN DARPin Domains or Product Candidates for such Collaboration Target, provided that the foregoing shall not apply to any MP DARPin Domains, any AGN DARPin Domains that are replaced, or any Collaboration Results related to AGN DARPin Domains or Product Candidates for Collaboration Targets that are replaced (and are no longer Collaboration Targets). During
Sample 1
Collaboration Results. Subject to the option rights of Bracco with regard to the Other Therapeutic Field as set forth in Section 4.3, Bracco grants to Dyax an exclusive worldwide license, with the right to sublicense, to the Collaboration Results generated by Bracco for all uses outside of the Collaboration Field. Should Dyax obtain rights with regard to any Dyax Lead in the Diagnostic Imaging Field pursuant to Section 5.2 or to any Dyax Lead or Collaboration Lead in the Collaboration Field pursuant Section 5.3, Dyax shall have an exclusive worldwide license, with the right to sublicense, to the specific Collaboration Results pertaining to the applicable Collaboration Lead and a nonexclusive worldwide license, with the right to sublicense, to use the generally useful Collaboration Results in connection therewith. Dyax's rights to the Collaboration Lead and the Collaboration Results in the Collaboration Field shall be subject to the diligence requirements of Section 5.5.
Sample 1
Collaboration Results. Tango shall maintain, and shall cause its Affiliates and their respective employees and permitted subcontractors to maintain, records regarding its or their conduct of activities under the Research Collaboration, which may be in the form of electronic lab notebooks that are segregated from other activities not performed under this Agreement, for so long as necessary after the applicable activity to comply with Applicable Laws or to support the prosecution, maintenance and enforcement of intellectual property rights (including Patent Rights) in accordance with Article 8, and as necessary in order to comply with its obligations under this Agreement, regarding its conduct of the Research Collaboration, but in no event less than [***]. Such records shall be maintained in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes (and as otherwise necessary to comply with its obligations under this Agreement) and shall reflect the work done by or on behalf of Tango in the performance of the Research Collaboration, including all Collaboration Results. During such record retention period, Gilead shall have the right, during normal business hours and upon reasonable notice not more than [***], to inspect and copy Collaboration Results.
Sample 1
Collaboration Results. Arrowhead shall not publicly disclose any Collaboration Results without the express written consent of Amgen, which consent may be granted or withheld in Amgen’s sole discretion.
Sample 1
AutoNDA by SimpleDocs
Collaboration Results 
Sample 1

Related to Collaboration Results

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

Time is Money Join Law Insider Premium to draft better contracts faster.